
LT3+LT4 Therapy May Elevate Psychiatric Morbidity Risk in Autoimmune Hypothyroidism
In a Swedish nationwide cohort of 184,266 adults with autoimmune hypothyroidism, starting liothyronine (LT3) in combination with levothyroxine (LT4) was linked to a 43% higher risk of any psychiatric morbidity (adjusted HR 1.43) versus LT4 alone, with similar increases for affective/anxiety (HR 1.44) and psychotic morbidity (HR 1.46). The associations held across sexes and ages under 75, and were especially elevated for psychotic morbidity among women and those under 30. Limitations include retrospective design and potential confounding; authors note LT3 use may reflect emerging mental-health issues rather than causation.













